Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2017

View Archived Issues

CARB-X grant supports Vedanta's development of human microbiome drug candidate VE-303

Takeda recaps highlights of second quarter of fiscal 2017

NousCom raises series B financing to advance neoantigen-based cancer vaccines

Krystal Biotech receives equity-based award to support epidermolysis bullosa work

Preclinical evaluation of first-in-class nucleic acid therapeutic RCT-201

Novel BTK inhibitor PRN-2246 demonstrates efficacy in multiple sclerosis model

AT-527 well tolerated and reduces HCV RNA in phase Ia trial

Cancer-targeted theranostic probe [177Lu]DOTA-NIR-790 effective in vivo

Study with pramlintide supports theoretical basis for Alzheimer's disease treatment

Klotho Therapeutics announces series A financing to advance patent pending version of Klotho

Patient dosing begins in ORION-11 study of inclisiran

FDA approves Zelboraf for Erdheim-Chester disease

NanoCarrier obtains license to VB-111 in Japan

Ionis submits NDA to FDA for inotersen for hereditary TTR amyloidosis

New study launched under collaborative Alzheimer's Prevention Initiative Generation program

FDA lifts clinical hold on phase I trials of UCART-123

AnaptysBio reports topline phase I results for ANB-019

Wave Life Sciences commences phase I study of WVE-210201 for DMD

FDA approves Alecensa for ALK+ metastatic NSCLC

Eutilex enters immuno-oncology partnership with Zhejiang Huahai Pharmaceutical

Bristol-Myers Squibb presents ROM-K channel blockers for hypertension

Stealth BioTherapeutics begins MMPOWER-3 phase III study of elamipretide

Boehringer Ingelheim discloses orexin OX1 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...